The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Grinshpun, Albert; Sandusky, Zachary M; Jeselsohn, Rinath

Grinshpun, Albert; Sandusky, Zachary M; Jeselsohn, Rinath.

Affiliation

Grinshpun A; Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sandusky ZM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jeselsohn R; Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: rinath_jeselsohn@dfci.harvard.edu.

Hematol Oncol Clin North Am ; 37(1): 169-181, 2023 02.

Article in En | MEDLINE | ID: mdl-36435608

Subject(s)

Breast Neoplasms; Humans; Female; Breast Neoplasms/drug therapy; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Estrogen Receptor alpha/genetics; Estrogen Receptor alpha/chemistry; Receptors, Estrogen/genetics; Receptors, Estrogen/therapeutic use; Mutation

Key words

Breast cancer; ESR1 mutation; Endocrine resistance; Endocrine treatment; Estrogen receptor; ctDNA

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Hematol Oncol Clin North Am Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2023 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google